Cancer Research
Engineered Immune Cells Show Promise Against Advanced Cancer in Early Trial
Scientists modified patients' immune cells to better recognize and attack cancer tumors expressing NY-ESO-1 protein.
Clinical Trial
Mar 28, 2026 0
Results for "Partial Epigenetic Reprogramming" in Cancer
20 articles
Cancer Research
Engineered T Cells Show Promise Against Childhood Cancers in Phase I Trial
Modified immune cells targeting GD2 protein demonstrated safety in treating aggressive childhood cancers like neuroblastoma and osteosarcoma.
Clinical Trial
Mar 28, 2026 0
Cancer Research
Low-Dose Gut Radiation Revives Immune Checkpoint Therapy in Drug-Resistant Cancers
A phase II trial tests whether 1Gy intestinal radiation can re-sensitize solid tumors that have stopped responding to immunotherapy.
Clinical Trial
Jul 1, 2026 0
Cancer Research
Apalutamide Plus Immunotherapy Combo Trial for Rare Prostate Cancer Variant Terminated
A Phase 2 trial testing AR blockade combined with PD-1 inhibition in treatment-emergent neuroendocrine prostate cancer was terminated early.
Clinical Trial
May 15, 2026 0
Cancer Research
PULSAR Radiation Plus IMSA101 Immunotherapy Trial in Oligoprogressive Cancers Terminated Early
A Phase 2 trial combining adaptive stereotactic radiotherapy with IMSA101 and checkpoint inhibitors was halted after enrolling only 16 patients.
Clinical Trial
May 14, 2026 0
Cancer Research
Modified T Cells Show Promise Against Childhood Blood Cancers in NCI Trial
Researchers modified children's own immune cells to fight B-cell leukemia and lymphoma when standard treatments failed.
Clinical Trial
Mar 28, 2026 0
Cancer Research
Strength Training Fights Inflammaging in Bone Marrow Transplant Survivors
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
Clinical Trial
May 25, 2026 0
Cancer Research
Time-Restricted Eating Shows Promise for Breast Cancer Survivors Over 60
Eight-week study of weekday-only intermittent fasting in older breast cancer survivors with overweight demonstrates feasibility.
Clinical Trial
Mar 28, 2026 0
Cancer Research
Amgen's PSMA Bispecific T-Cell Engager Acapatamab Tested in Advanced Prostate Cancer
Phase 1 trial of acapatamab, a PSMA-targeting bispecific T-cell engager, enrolls 212 men with metastatic castration-resistant prostate cancer.
Clinical Trial
May 13, 2026 0
Cancer Research
Brain Cancer Trial Uses Patient's Own Tumor Cells to Train Immune System
Innovative immunotherapy approach converts patient tumor cells into personalized vaccines to fight aggressive brain cancer.
Clinical Trial
Mar 28, 2026 0
Cancer Research
Blood Test Detects Hidden Cancer Cells After Colorectal Surgery Using Exosomes
New liquid biopsy technique identifies molecular residual disease in colorectal cancer patients to guide personalized treatment decisions.
Clinical Trial
Mar 28, 2026 1
Cancer Research
Melanoma Drug Resistance Linked to Cellular Communication Vesicles Called Exosomes
French researchers studied how tiny cellular packages called exosomes may help melanoma cells resist treatment and spread throughout the body.
Clinical Trial
Mar 28, 2026 0
Cancer Research
HDAC Inhibitor Plus Checkpoint Blocker Tested in Advanced Lung Cancer Trial
A phase 1/2 trial combined mocetinostat and durvalumab in 83 patients with advanced solid tumors and NSCLC.
Clinical Trial
May 7, 2026 0
Cancer Research
Engineered T Cells Show Promise Against Deadly Mesothelioma Cancer
Small trial tests modified immune cells injected directly into chest cavity to fight aggressive cancer with 12-month survival rate.
Clinical Trial
Mar 28, 2026 1
Cancer Research
Turin Study Maps Why Multiple Myeloma Escapes Anti-CD38 Immunotherapy
Italian researchers track genomic and cellular changes in myeloma patients to uncover why anti-CD38 treatments stop working.
Clinical Trial
Jun 16, 2026 0
Cancer Research
Liquid Biopsy for Sarcoma: Can cfDNA and Telomere Mutations Predict Recurrence
Researchers explored whether cancer-derived cell-free DNA and telomere maintenance mutations could serve as early warning biomarkers in soft tissue sarcoma patients.
Clinical Trial
May 16, 2026 0
Cancer Research
T-VEC Plus Pembrolizumab Tested in Melanoma After Anti-PD-1 Failure
Phase 2 trial explores whether combining oncolytic virus therapy with immunotherapy can rescue patients whose melanoma progressed on PD-1 blockade.
Clinical Trial
May 29, 2026 0
Cancer Research
12-Week Exercise Program Targets Body Composition in Breast Cancer Survivors
A completed trial examines how structured exercise reshapes body composition and sustains physical activity habits in breast cancer patients post-diagnosis.
Clinical Trial
Jun 17, 2026 0
Cancer Research
Enhanced CAR-T Cell Therapy Shows Promise Against Treatment-Resistant Blood Cancers
Modified immune cells engineered to overcome cancer's defenses completed safety testing in lymphoma patients.
Clinical Trial
Mar 29, 2026 12
Cancer Research
Pfizer Tests BCMA Bispecific Antibody Elranatamab in Relapsed Multiple Myeloma
Phase 1 trial evaluates PF-06863135 (elranatamab) alone and with immunomodulatory agents to find safe dosing in heavily pretreated myeloma patients.
Clinical Trial
Jun 24, 2026 0
Page 1 of 2Next